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Abstract
Background Leuprorelin acetate, a luteinizing hormone-
releasing hormone agonist, is used worldwide in pre-
menopausal women with hormone receptor-positive breast
cancer. This study was conducted to assess the non-infe-
riority of the 6-month depot formulation, TAP-144-SR
(6M) 22.5 mg to the 3-month depot formulation, TAP-144-
SR (3M) 11.25 mg in postoperative, premenopausal
patients with hormone receptor-positive breast cancer.
Methods This was a 96-week phase III, randomized,
open-label, parallel-group comparative study. All patients
concomitantly received oral tamoxifen (20 mg daily). The
primary endpoint was the suppression rate of serum
estradiol (E2) to the menopausal level (B30 pg/mL) from
Week 4 through Week 48.
Results In total, 167 patients were randomized to receive
TAP-144-SR (6M) (n = 83) or TAP-144-SR (3M)
(n = 84) and the E2 suppression rate was 97.6 and 96.4 %,
respectively. The estimated between-group difference was
1.2 % (95 % confidence interval -5.2 to 7.8). The non-
inferiority of TAP-144-SR (6M) to TAP-144-SR (3M) for
E2 suppression was confirmed. As for safety, common
adverse events were hot flush and injection site reactions
including induration, pain, and erythema in both treatment
groups, which were of BGrade 2 in severity and not
serious. No significant between-group differences in safety
profiles and tolerability were observed.
Conclusions TAP-144-SR (6M) was not inferior to TAP-
144-SR (3M) for its suppressive effect on serum E2. TAP-
144-SR (6M) was also as well tolerated as TAP-144-SR
(3M).
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Introduction
For the treatment of premenopausal women with hormone
receptor-positive breast cancer, it is highly important to
suppress estrogen production through ovarian function
suppression (OFS). OFS therapy with a luteinizing hor-
mone–releasing hormone (LH–RH) agonist, in combina-
tion with adjuvant tamoxifen or chemotherapy is widely
used for postoperative premenopausal endocrine-respon-
sive breast cancer patients [1–7]. However, the optimal
treatment duration of postoperative adjuvant endocrine
therapy with an LH–RH agonist alone or in combination
with tamoxifen is still controversial [8–10]. Although
premenopausal hormone receptor-positive breast cancer
patients have a relatively good prognosis, the risk of
recurrence remains at 5 years or longer after surgery,
suggesting the importance of long-term endocrine therapy
for 5 years or longer for the treatment of patients at high
risk for recurrence [11].
Leuprorelin acetate (leuprorelin), an LH–RH agonist is
commonly used for the treatment of patients with hormone-
responsive prostate cancer and premenopausal breast
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cancer worldwide. It is available in 1- and 3-month depot
formulations for both cancers, and a 6-month depot for-
mulation for prostate cancer.
A 6-month depot formulation, TAP-144-SR (6M), was
initially developed for prostate cancer in Japan and a phase
II study was conducted in treatment-naı¨ve prostate cancer
patients. The results showed that the optimal clinical
dosage of TAP-144-SR (6M) in Japan is 22.5 mg [12].
In parallel with the phase III study in prostate cancer,
this phase III study was also conducted in Japan for the first
time to assess the non-inferiority of TAP-144-SR (6M)
22.5 mg to TAP-144-SR (3M) 11.25 mg regarding its
suppressive effect on serum estradiol (E2), and to evaluate
its efficacy and safety in postoperative, premenopausal
patients with hormone receptor-positive breast cancer.
Patients and methods
Study design
A phase III, randomized, open-label, parallel-group com-
parative study of TAP-144-SR (6M) to TAP-144-SR (3M)
was conducted to evaluate the efficacy, safety, and phar-
macokinetics of the 2 formulations and hormone levels in
postoperative, premenopausal patients with endocrine-re-
sponsive breast cancer. Following a 4-week screening per-
iod, eligible patients were randomly assigned at a 1:1 ratio to
receive injection of either TAP-144-SR (6M) 22.5 mg (6M
group) or TAP-144-SR (3M) 11.25 mg (3M group) for
96 weeks using dynamic allocation with the number of
positive axillary lymph nodes (0, 1–3, C4), tumor diameter
(B2.0, [2.0 cm), estrogen receptor (ER)/progesterone
receptor (PgR) status (ER?/PgR?, ER?/PgR-, ER-/
PgR?), age (at the time of consent;B39, 40–44,C45 years),
pre- and post-operative chemotherapy (presence, absence),
and study site as factors. All patients in both groups con-
comitantly received oral tamoxifen citrate (20 mg daily)
throughout the 96-week study period.
This study was conducted in accordance with the Interna-
tional Conference on Harmonisation of Good Clinical Prac-
tice Guidelines, the principles of the Declaration of Helsinki,
and all applicable laws and regulations, at 20 medical centers
in Japan between April 2012 and December 2014. The pro-
tocol was reviewed and approved by the Institutional Review
Boards of all study participating sites. All patients provided
written informed consent before enrollment. The clinical trial
registration number is NCT01546649.
Patients
Japanese premenopausal patients with histologically con-
firmed primary breast cancer who met the following
criteria were eligible: age C20 years; both or either ER?
or PgR?, and human epidermal growth factor receptor type
2 (HER-2)-negative primary tumor; T1–T3, any N, and M0
according to the TNM classification; any type of surgical
procedure (in case of breast-conserving surgery, postoper-
ative radiation to the breast was required); any type of
preoperative and/or postoperative adjuvant chemotherapy
prior to enrollment; history of regular menstruation or
follicle-stimulating hormone (FSH) of\40 mIU/mL and E2
of C10 pg/mL within 12 weeks prior to enrollment and not
having chemical menopause (FSH of C40 mIU/mL and E2
of \10 pg/mL) within 12 weeks after completion of the
postoperative chemotherapy; capable of receiving the study
drug and tamoxifen within 12 weeks after surgery or after
postoperative chemotherapy completion prior to enroll-
ment; Eastern Cooperative Oncology Group performance
status of Grade 0 or 1.
Exclusion criteria included the following: endocrine
therapy prior to surgery or postoperative endocrine therapy
before enrollment; bilateral oophorectomy or ovarian
irradiation; inflammatory breast cancer or bilateral breast
cancer; non-invasive ductal carcinoma, multiple cancers or
a history of cancer in other organs; QTcF interval
exceeding 460 ms on the 12-lead electrocardiogram (ECG)
at screening.
Primary and secondary endpoints
The primary endpointwas the suppression rate of serumE2 to
the menopausal level (B30 pg/mL), which is the best index
of the medicinal effect of leuprorelin, from Week 4 through
Week 48. The secondary endpoints included: serum E2, LH,
and FSH concentrations; disease-free survival [DFS; defined
as the time from random assignment to disease event (re-
currence, second primary cancer, or death)] and distant DFS
[DDFS; defined as the time from random assignment to
disease event (distant recurrence, second primary cancer, or
death)] throughout the study period as measures of the long-
term efficacy. All the serum hormone concentrations were
measured at a central laboratory (SRL Medisearch Inc.,
Tokyo, Japan). Electrochemiluminescence immunoassay for
E2 (ECLusys
E2III, Roche Diagnostics K.K., Tokyo,
Japan), chemiluminescence immunoassay for LH
(ARCHITECT  LH, Abbott Japan, Chiba, Japan) and
chemiluminescence immunoassay for FSH (ARCHITECT
 FSH, Abbott Japan, Chiba, Japan) were used to measure
each serum hormone concentration.
Pharmacokinetic analysis was performed by measuring
the serum concentrations of unchanged TAP-144 using LC/
MS/MS from the start of the study drug administration
through Week 48.
Safety data were obtained from the findings of clinical
signs/symptoms, body weight, vital signs, laboratory test
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results, 12-lead ECG, and bone mineral density (BMD)
measured by dual-energy X-ray absorptiometry throughout
the study period. Adverse events (AEs) were recorded and
graded according to the National Cancer Institute Common
Terminology Criteria for Adverse Events version 4.0.
Statistical analysis
The required sample size was estimated as 74 subjects in
each treatment group, a total of 148 subjects, based on
which the conditions were set as a non-inferiority margin
of 10 %, with a two-sided alpha level of 0.05, ensuring
80 % power. Taking a possible drop-out rate of 10 % into
consideration, 82 patients in each treatment group, thus a
total of 164 patients were required.
The Full Analysis Set (FAS) was defined as all patients
who were randomized and received at least 1 dose of the
study drug, and the Hormone Analysis Set (HAS) was
defined as the patients who had no major protocol devi-
ations, and in whom the primary endpoints were evalu-
able. The FAS was used for the primary and secondary
endpoints and the HAS was used to examine the robust-
ness of the results of the primary analysis. The treatment
difference [TAP-144-SR (6M) - TAP-144-SR (3M)] and
the two-sided 95 % confidence interval (CI) were calcu-
lated by a method based on the Wilson score method [13].
If the lower bound of the two-sided 95 % CI was greater
than the prespecified non-inferiority margin of -10 %,
clinical non-inferiority of TAP-144-SR (6M) to TAP-144-
SR (3M) would be declared. Summary statistics were
obtained for the secondary efficacy endpoints. Serum E2
concentrations lower than or equal to the limit of quan-
tification (10 pg/mL) were considered to be 0 pg/mL.
DFS and DDFS were estimated by the Kaplan–Meier
method.
For the safety analysis, AEs and their severity were
analyzed by treatment group. AEs were summarized in the
Safety Data Analysis Set (SAS) defined as all patients who
were randomized and received at least 1 dose of the study
drug and were coded by the System Organ Class Preferred
Terms based on the Medical Dictionary for Regulatory
Activities (MedDRA) terminology, version 16.1.
As for pharmacokinetic analysis, summary statistics
were calculated for serum unchanged-TAP-144 concen-
trations through Week 48 in the Pharmacokinetics Analysis
Set (PAS; defined as the population of patients in the FAS
in whom serum unchanged-TAP-144 concentrations were
appropriately measured), and for pharmacokinetic param-
eters in patients in whom serum unchanged-TAP-144
concentrations were measured at 3 and 6 h after the study
drug administration in the PAS.
Results
Patient demographics
Figure 1 shows the patient disposition. Of the 180 patients
who provided written informed consent, a total of 167
patients were randomized, 83 patients received TAP-144-
SR (6M) and 84 patients received TAP-144-SR (3M).
Overall, 150 patients (75 patients in each treatment group)
completed the 96-week study treatment, and the majority
of patients (92.8 and 91.7 % in the 6M and 3M groups,
respectively) received the maximum doses (4 doses and 8
doses in the 6M and 3M groups, respectively).
The baseline demographic and disease characteristics of
patients are summarized in Table 1. No major differences




For the primary endpoint, the suppression rate of serum E2
to the menopausal level (B30 pg/mL) from Week 4
through Week 48 in the FAS was 97.6 % (95 % CI
91.6–99.7) in the 6M group and 96.4 % (95 % CI
89.9–99.3) in the 3M group (Table 2). The estimated
between-group difference in the suppression rate was
1.2 % (95 % CI -5.2 to 7.8). Since the lower CI was more
than the pre-determined non-inferiority margin of -10 %,
the non-inferiority of TAP-144-SR (6M) to TAP-144-SR
(3M) was confirmed for the suppressive effect on serum E2.
Five patients (2 and 3 patients in the 6M and 3M groups,
respectively) had a serum E2 concentration exceeding
30 pg/mL during the period from the start of study drug
administration to Week 48, which was measured at only 1
assessment time point in each patient. For the sensitivity
analysis, the same analysis as for the primary analysis was
utilized in the HAS as the secondary analysis. Similar
results were obtained in the HAS [between-group differ-
ence in the suppression rate, 2.4 % (95 % CI -3.8 to 9.2)].
Therefore, the non-inferiority of TAP-144-SR (6M) to
TAP-144-SR (3M) was confirmed in both analysis sets.
Changes in the hormone levels and menstrual status
The median serum E2 concentrations significantly declined
to the value of 0 pg/mL, below the menopausal level of
B30 pg/mL from Week 4 through Week 48 (Fig. 2), and
remained at the suppressed level until Week 96 in both
treatment groups.
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Similarly, the median serum LH and FSH concentrations
were suppressed to the levels of B1 and B2.5 mIU/mL,
respectively from Week 4, and remained at the low levels
through Week 96 in both treatment groups. There were no
significant differences in the changes in these hormone
levels between the treatment groups.
Throughout the study period, all patients achieved
amenorrhea from Week 8, except 1 patient in the 6M group
who had menses at Week 8.
DFS and DDFS
Throughout the 96-week study period, there were 4 disease
events (2 each in the 6M and 3M groups, respectively): 3
recurrences (2 and 1), and 1 s primary cancer in the 3M
group. One recurrence in the 6M group was bone metastasis.
The DFS rate at Week 96 in the FAS was 97.3 % (95 % CI
93.6–100.0) and 97.5 % (95 %CI 94.1–100.0) in the 6Mand
3M groups, respectively, with no significant between-group
differences (estimated difference,-0.2 % [95 %CI-5.2 to
4.9]). The DDFS rate at Week 96 in the FAS was 98.5 %
(95 % CI 95.7–100.0) and 98.8 % (95 % CI 96.4–100.0) in
the 6M and 3M groups, respectively. There were no signif-
icant differences between the treatment groups (estimated
difference, -0.3 % [95 % CI -4.0 to 3.4]).
Pharmacokinetics
Serum TAP-144 concentrations rapidly increased imme-
diately after the administration of TAP-144-SR (6M), and
then rapidly decreased through Day 8 (Fig. 3). Thereafter,
they increased again from Week 2 through Week 3, and
gradually declined through Week 24, showing a double-
peak of TAP-144. The profile of serum TAP-144 concen-
trations after the initial administration was similar to that
after the second administration. In contrast, serum TAP-
144 concentration rapidly increased 1 h after the adminis-
tration of TAP-144-SR (3M), and then gradually declined
during the period from 3 to 12 h. The maximum drug
concentration (Cmax) in the 6M group was approximately
one-fifth of that in the 3M group, and the area under the
blood concentration–time curve in the 6M group was
approximately 1.8 times that in the 3M group (data not
shown). No obvious accumulation was observed either
with TAP-144-SR (6M) or TAP-144-SR (3M).
Safety
Throughout the study period, 98.8 % (82/83) and 97.6 %
(82/84) of patients experienced AEs in the 6M and 3M
groups, respectively The most common AEs were hot flush,
followed by nasopharyngitis, radiation skin injury, injec-
tion site induration, injection site pain, white blood cell
count decreased, headache and arthralgia, with no signifi-
cant differences between the 2 groups (Table 3). The
incidence of a series of injection site reactions (induration,
pain, erythema, etc.) was 57.8 % (48/83) and 60.7 % (51/
84) of patients in the 6M and 3M groups, respectively.
Most AEs were Grade 1 or 2 in severity. AEs of Grade 3
were reported in 14 (16.9 %) and 18 patients (21.4 %) in
the 6M and 3M groups, respectively; AEs of Grade 4 were
reported in 1 patient (1.2 %) in the 6M group. Drug-related
Fig. 1 Patient disposition.
n number of patients evaluated,
AE adverse event
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AEs of CGrade 3 were anal fistula, blood triglycerides
increased, liver function tests abnormal, hyperlipidaemia
and interstitial lung disease (1 patient each) in the 6M
group, and gamma-glutamyltransferase increased (3
patients), hypertension (2 patients), weight increased,
neutropenia, blood triglycerides increased and interstitial
lung disease (1 patient each) in the 3M group.
Serious AEs (SAEs) were reported in 6 (7.2 %) and 7
patients (8.3 %) in the 6M and 3M groups, respectively,
and included 3 drug-related SAEs: interstitial lung disease
in 1 patient in each group and anal fistula in 1 patient in the
6M group.
AEs leading to discontinuation of the study drug
occurred in 4 (4.8 %) and 5 patients (6.0 %) in the 6M and
Table 1 Baseline demographic
and disease characteristics of
patients (FAS)
Variable Treatment group Total (n = 167)
n (%)
TAP-144-SR (6M) (n = 83)
n (%)
TAP-144-SR (3M) (n = 84)
n (%)
Age (years)
B39 13 (15.7) 12 (14.3) 25 (15.0)
40–44 29 (34.9) 30 (35.7) 59 (35.3)
C45 41 (49.4) 42 (50.0) 83 (49.7)
Mean ± SD 44.2 ± 4.9 44.0 ± 5.2 44.1 ± 5.0
BMI (kg/m2)
Mean ± SD 21.5 ± 3.0 21.5 ± 2.9 21.5 ± 3.0
Tumor stage (TNM classification)
I 61 (73.5) 61 (72.6) 122 (73.1)
IIA 19 (22.9) 21 (25.0) 40 (24.0)
IIB 2 (2.4) 2 (2.4) 4 (2.4)
IIIA 1 (1.2) 0 (0.0) 1 (0.6)
Tumor size (cm)
B2.0 65 (78.3) 66 (78.6) 131 (78.4)
[2.0 18 (21.7) 18 (21.4) 36 (21.6)
Number of positive axillary lymph nodes
0 68 (81.9) 70 (83.3) 138 (82.6)
1–3 15 (18.1) 14 (16.7) 29 (17.4)
ER/PgR expression
ER?/PgR? 82 (98.8) 82 (97.6) 164 (98.2)
ER?/PgR- 1 (1.2) 2 (2.4) 3 (1.8)
ER-/PgR? 0 (0.0) 0 (0.0) 0 (0.0)
Radiation therapy
Presence 52 (62.7) 59 (70.2) 111 (66.5)
Absence 31 (37.3) 25 (29.8) 56 (33.5)
Pre- and postoperative chemotherapy
Presence 0 (0.0) 1 (1.2) 1 (0.6)
Absence 83 (100.0) 83 (98.8) 166 (99.4)
Serum estradiol (pg/mL) at Week 0
Mean ± SD 168.0 ± 163.0 138.2 ± 125.5 153.0 ± 145.7
FAS full analysis set, BMI body mass index, SD standard deviation, ER estrogen receptor, PgR progesterone
receptor
Table 2 Suppression rate of serum estradiol to the menopausal levels (B30 pg/mL) from Week 4 through Week 48 (FAS)
TAP-144-SR (6M) (n = 83) TAP-144-SR (3M) (n = 84)
Suppression rate of serum estradiol [% (95 % CI)] 97.6 (91.6, 99.7) 96.4 (89.9, 99.3)
TAP-144-SR (6M) - TAP-144-SR (3M) [% (95 % CI)] 1.2 (-5.2, 7.8)
FAS full analysis set, E2 estradiol, CI confidence interval
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3M groups, respectively. Of these, AEs for which a causal
relationship could not be ruled out were found in 4 patients
(palpitations in 1 patient, joint stiffness, menopausal
symptoms, and dry skin in 1, liver function test abnormal in
1, and interstitial lung disease in 1) in the 6M group, and in
4 patients (radiation pneumonitis in 1 patient, gamma-
glutamyltransferase increased in 1, genital hemorrhage in
1, and interstitial lung disease in 1) in the 3M group. There
were no deaths throughout the study period.
For ECG data analysis, QTcF intervals declined from
the baseline values through 6 h after the study drug
administration in both treatment groups, and no transient
prolongation of QTcF intervals was detected at around the
time of the Cmax. The mean changes (SD) in QTcF
intervals from baseline were 9.7 (15.36) ms at Week 4, 9.2
(14.76) ms at Week 48, and 8.4 (14.73) ms at Week 96 in
the 6M group, and 11.4 (13.83) ms at Week 4, 10.8 (15.13)
ms at Week 48, and 13.1 (22.03) ms at Week 96 in the 3M
group. Prolonged QTcF intervals of approximately 10 ms
were observed from Week 4 through Week 96 in both
treatment groups. Prolonged QTcF intervals of [60 ms
from baseline were reported in 3 patients (2 and 1 in the
6M and 3M groups, respectively), which were transient and
detected only at 1 assessment time point in each patient. At
7 institutions where it was possible to measure ECG at all
assessment points, including 3 and 6 h after the study drug
administration, the same ECG for all patients was used, and
a total of 54 patients were interpreted at the central reading
Fig. 2 Time course of serum estradiol concentration from the start of study drug administration through Week 48 (FAS). Data are presented as
the median and the 75th percentile. E2 estradiol, FAS full set analysis
Fig. 3 Time course of serum
TAP-144 concentration from
the start of study drug
administration through week 24
(PAS). Data indicate the
mean ? SD. SD standard
deviation, PAS
pharmacokinetics analysis set
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center. Prolonged QTcF intervals of approximately 15 ms
were observed from Week 4 through Week 96 in both
treatment groups. Similar prolonged QTcF intervals to
those observed in the ECG measurements at the institutions
were also observed in the measurements at the central
reading center.
For BMD of the lumbar spine (L2–L4), the mean change
from baseline tended to gradually decline over time in both
treatment groups. The mean change rate in BMD from
baseline at Week 48 and Week 96 were -5.1 % (95 % CI
-5.8 to -4.5) and -7.6 % (95 % CI -8.5 to -6.8) in the
6M group, and -4.7 % (95 % CI -5.5 to -4.0) and
-6.7 % (95 % CI -7.7 to -5.8) in the 3M group. There
were no significant differences in the BMD reduction
between the treatment groups (Fig. 4).
Discussion
This is the first report evaluating the efficacy and safety of
6-monthly injections of TAP-144-SR (6M) 22.5 mg in
postoperative, premenopausal patients with hormone-
receptor positive breast cancer. As for the primary end-
point, TAP-144-SR (6M) was non-inferior to TAP-144-SR
(3M) for the effect to suppress the serum E2 to the
menopausal level from Week 4 through Week 48.
TAP-144-SR (1M) and TAP-144-SR (3M) were effec-
tive to suppress the serum E2 level to a menopausal level in
premenopausal breast cancer patients at the same dose at
which suppression of serum testosterone to the castrate
level was achieved in prostate cancer patients in clinical
studies [14–16]. Therefore, the phase III study was con-
ducted at the injection dose of TAP-144-SR (6M) 22.5 mg,
which was determined in the phase II study for Japanese
treatment-naı¨ve prostate cancer patients [12]. The results
showed that the injection dose of TAP-144-SR (6M)
22.5 mg, which was successfully used to suppress serum
testosterone to the castrate level in prostate cancer patients
[17], was also effective in premenopausal breast cancer
patients (Fig. 2). In addition, TAP-144-SR (6M) was as
effective as TAP-144-SR (3M) to suppress the serum LH
and FSH levels from Week 4 through Week 96 in these
patients. All patients also achieved amenorrhea from Week
8, except 1 patient in the 6M group who experienced
Table 3 Adverse events
occurring in 10 % or more of
patients in any treatment group
(SAS)
Preferred terma TAP-144-SR (6M) (n = 83)
n (%)
TAP-144-SR (3M) (n = 84)
n (%)
Patients with any AEs 82 (98.8) 82 (97.6)
Hot flush 43 (51.8) 48 (57.1)
Nasopharyngitis 47 (56.6) 42 (50.0)
Radiation skin injury 31 (37.3) 39 (46.4)
Injection site induration 36 (43.4) 33 (39.3)
Injection site pain 24 (28.9) 26 (31.0)
White blood cell count decreased 27 (32.5) 19 (22.6)
Headache 21 (25.3) 19 (22.6)
Arthralgia 18 (21.7) 20 (23.8)
Malaise 13 (15.7) 13 (15.5)
Injection site erythema 13 (15.7) 8 (9.5)
Musculoskeletal stiffness 11 (13.3) 9 (10.7)
Weight increased 12 (14.5) 8 (9.5)
Back pain 13 (15.7) 6 (7.1)
Insomnia 10 (12.0) 9 (10.7)
Injection site swelling 12 (14.5) 5 (6.0)
Hyperhidrosis 9 (10.8) 7 (8.3)
Nausea 7 (8.4) 9 (10.7)
Constipation 13 (15.7) 2 (2.4)
Dizziness 6 (7.2) 9 (10.7)
Gamma-glutamyltransferase increased 3 (3.6) 12 (14.3)
Rash 9 (10.8) 6 (7.1)
Eczema 3 (3.6) 9 (10.7)
SAS safety data analysis set, AE adverse event
a MedDRA, version 16.1
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menses at Week 8. It was therefore suggested that ovarian
function was substantially suppressed by treatment with
TAP-144-SR (6M) 22.5 mg every 24 weeks.
In this study, there were no significant differences in the
DFS and DDFS at Week 96 between the groups. There are
several reports that more than 3 or 4 years after surgery, the
risk of recurrence is higher in ER-positive patients than ER-
negative patients [18, 19], whichmay indicate that the risk of
recurrence must be reduced by postoperative adjuvant hor-
mone or chemotherapy for a longer period after surgery in
ER-positive patients. At the St Gallen International Expert
Consensus meetings, both postoperative tamoxifen and
tamoxifen plus ovarian function suppression for 5 years
were considered acceptable as the standard treatment for
premenopausal patients with hormone-receptor positive
breast cancer [10]. Furthermore, the results of the Suppres-
sion of Ovarian Function Trial (SOFT) showed that 5-year
treatment with tamoxifen plus ovarian suppression might
provide a benefit for DFS in high-risk patients younger than
35 years who have remained premenopausal after adjuvant
chemotherapy, compared to tamoxifen alone [20]. There-
fore, long-term administration of an LH–RH agonist is a
possibility in high risk premenopausal patients with endo-
crine-responsive breast cancer.
In the PK analysis, TAP-144-SR (6M) showed a double-
peak of TAP-144, similar to the results in the PK analysis
obtained in previous Japanese clinical trials in prostate
cancer patients [12], which demonstrated that the clinically
sufficient drug concentration to suppress ovarian function
was maintained throughout a period of 24 weeks with a
single injection (Fig. 3). The serum TAP-144 concentration
profile after the initial administration of TAP-144-SR (6M)
was similar to that after its second administration.
As for safety, there were no significant differences in the
safety profiles and tolerability between the groups,
regarding the incidence, type and severity of AEs. The
most common drug-related AEs included menopausal
symptoms such as hot flush, headache and arthralgia, and
injection site reactions (Table 3). A series of injection site
reactions were reported in about 60 % of patients in each
group with no significant between-group differences in the
incidence and severity. All of these events were BGrade 2
in severity, and no cases led to discontinuation due to
injection site reactions.
During the study period, 3 serious drug-related AEs
were reported: interstitial lung disease in 1 patient in each
treatment group and anal fistula in 1 patient in the 6M
group. Both patients with interstitial lung disease had
postoperative radiation and adjuvant endocrine therapy in
the same period. It is known that pulmonary fibrosis fre-
quently occurs following radiation therapy, and that
tamoxifen may cause the development of lung fibrosis by
inducing transforming growth factor-b. It was also reported
that tamoxifen treatment during post-mastectomy radiation
in breast cancer patients significantly increased the risk for
the development of lung fibrosis along with other prog-
nostic factors like age and menopausal status [21]. Since
the pathogenesis of interstitial lung disease is still unclear,
further research is necessary to evaluate whether the con-
comitant implementation of radiation and adjuvant TAP-
144 plus tamoxifen therapy is associated with interstitial
lung disease.
As for the ECG data, there was not a tendency of QTcF
interval prolongation around the time of Cmax, and the
mean change in QTcF intervals from Week 4 through
Week 96 was approximately 10 ms in each treatment
Fig. 4 Time course of the
mean change rates from
baseline in bone mineral density
of the lumbar spine in patients
throughout the 96 week study
period (SAS). Data indicate the
mean ? SD. SD standard
deviation, SAS safety analysis
set
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group. It is considered that this QTcF prolongation may not
be primarily due to the pharmacological effect of TAP-144,
but be secondary to the suppression of ovarian E2 pro-
duction. A study of the effects of sex hormones on QTcF
interval prolongation suggests that estrogen might be a risk
factor for drug-induced torsades de pointes. Although E2
may influence clinically relevant QT interval prolongation,
the pathogenesis is still not clear [22].
Although BMD tended to gradually decline over time in
both treatment groups, the changes in BMD in TAP-144-
SR (6M) were similar to those of the results of our previous
clinical study in TAP-144-SR (3M) (Fig. 4) [23]. It is well
recognized that serum E2 level suppression with an LH–RH
agonist can cause BMD reduction, which can be prevented
or mitigated with the concomitant use of anti-osteoporosis
drugs [24].
In this phase III study, the non-inferiority of TAP-144-
SR (6M) 22.5 mg to TAP-144-SR (3M) at 11.25 mg was
confirmed in terms of the suppressive effect on serum E2 to
the menopausal level. No clinically significant other dif-
ferences in efficacy or tolerability were observed between
the treatment groups.
TAP-144-SR (6M) allows mitigation of the burden on
patients and physicians by reducing the dose frequency of
the treatment for premenopausal patients with endocrine-
responsive breast cancer. In particular, young pre-
menopausal patients who are busy with work and house-
work may derive great benefit from TAP-144-SR (6M).
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